Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Grants Longeveron Orphan Drug Designation for Lomecel-B in Infants with Hypoplastic Left Heart Syndrome

AmericanPharmaceuticalReviewDecember 07, 2021

Tag: ODD , HLHS , Lomecel-B , Longeveron

PharmaSources Customer Service